| Arginase is essential for survival of Leishmania donovani promastigotes but not intracellular amastigotes JM Boitz, CA Gilroy, TD Olenyik, D Paradis, J Perdeh, K Dearman, ... Infection and immunity 85 (1), 10.1128/iai. 00554-16, 2017 | 89 | 2017 |
| Controlled release of biologics for the treatment of type 2 diabetes CA Gilroy, KM Luginbuhl, A Chilkoti Journal of Controlled Release 240, 151-164, 2016 | 61 | 2016 |
| Spermidine synthase is required for virulence of Leishmania donovani C Gilroy, T Olenyik, SC Roberts, B Ullman Infection and immunity 79 (7), 2764-2769, 2011 | 61 | 2011 |
| Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action CA Gilroy, S Roberts, A Chilkoti Journal of Controlled Release 277, 154-164, 2018 | 49 | 2018 |
| Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia CA Gilroy, ME Capozzi, AK Varanko, J Tong, DA D'alessio, JE Campbell, ... Science advances 6 (35), eaaz9890, 2020 | 48 | 2020 |
| Genetic dissection of pyrimidine biosynthesis and salvage in Leishmania donovani ZN Wilson, CA Gilroy, JM Boitz, B Ullman, PA Yates Journal of Biological Chemistry 287 (16), 12759-12770, 2012 | 37 | 2012 |
| Oral putrescine restores virulence of ornithine decarboxylase-deficient Leishmania donovani in mice T Olenyik, C Gilroy, B Ullman Molecular and biochemical parasitology 176 (2), 109-111, 2011 | 29 | 2011 |
| Modular complement assemblies for mitigating inflammatory conditions KM Hainline, LS Shores, NL Votaw, ZJ Bernstein, SH Kelly, CN Fries, ... Proceedings of the National Academy of Sciences 118 (15), e2018627118, 2021 | 22 | 2021 |
| IMP dehydrogenase deficiency in Leishmania donovani causes a restrictive growth phenotype in promastigotes but is not essential for infection in mice AL Fulwiler, JM Boitz, C Gilroy, PA Yates, A Jardim, B Ullman Molecular and biochemical parasitology 180 (2), 123-126, 2011 | 16 | 2011 |
| Linking NE1545 gene expression with cell volume changes in Nitrosomonas europaea cells exposed to aromatic hydrocarbons TS Radniecki, CA Gilroy, L Semprini Chemosphere 82 (4), 514-520, 2011 | 16 | 2011 |
| Controlled Release Systems for Treating Type 2 Diabetes and Their Application Toward Multi-Agonist Combination Therapies CA Gilroy | 1 | 2019 |
| Dual agonist fusion proteins A Chilkoti, C Gilroy US Patent 11,649,275, 2023 | | 2023 |
| 1016-P: A Novel GLP-1 and FGF-21 Dual Agonist Drug Protects Mice from Obesity and Hyperglycemia CA Gilroy, M Capozzi, JC Su, J Tong, DA D’ALESSIO, J Campbell, ... Diabetes 68 (Supplement_1), 2019 | | 2019 |
| Sustained Release of FGF-21 from a Genetically Engineered Injectable Depot for the Treatment of Type 2 Diabetes CA Gilroy, A Chilkoti DIABETES 66, A289-A289, 2017 | | 2017 |
| Correlation of NE 1545 expression and cell size in Nitrosomonas europaea exposed to a suite of aromatic hydrocarbons CA Gilroy | | 2009 |
